Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade B 9.23 -0.86% -0.08
ADAP closed down 0.86 percent on Friday, July 10, 2020, on 25 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical ADAP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.86%
Bollinger Band Squeeze Range Contraction -0.86%
NR7 Range Contraction -0.86%
BB Squeeze + Lower Band Touch Range Contraction -0.86%
Lower Bollinger Band Touch Weakness -0.86%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.81%
Bollinger Band Squeeze Range Contraction -1.81%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Virotherapy Non Small Cell Lung Cancer Cancer Immunotherapy Ovarian Cancer Multiple Myeloma Melanoma Oncolytics Biotech Adoptive Cell Transfer Hematological Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Products Esophageal Cancer Breast And Lung Cancer

Is ADAP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.4
52 Week Low 0.709
Average Volume 3,903,860
200-Day Moving Average 3.71
50-Day Moving Average 7.95
20-Day Moving Average 9.74
10-Day Moving Average 9.57
Average True Range 0.83
ADX 21.53
+DI 20.47
-DI 16.32
Chandelier Exit (Long, 3 ATRs ) 8.73
Chandelier Exit (Short, 3 ATRs ) 11.33
Upper Bollinger Band 10.48
Lower Bollinger Band 9.00
Percent B (%b) 0.16
BandWidth 15.21
MACD Line 0.26
MACD Signal Line 0.48
MACD Histogram -0.221
Fundamentals Value
Market Cap 863.18 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -9.32
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.28
Resistance 3 (R3) 10.34 10.04 10.11
Resistance 2 (R2) 10.04 9.78 10.02 10.05
Resistance 1 (R1) 9.64 9.61 9.49 9.58 9.99
Pivot Point 9.34 9.34 9.27 9.32 9.34
Support 1 (S1) 8.94 9.08 8.79 8.88 8.47
Support 2 (S2) 8.64 8.91 8.62 8.41
Support 3 (S3) 8.24 8.64 8.36
Support 4 (S4) 8.18